Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Redesigned Purevision Contact Lens
Device: PureVision Contact Lens

First Posted Date: 2010-05-06

Last Posted Date: 2020-10-06

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 376

Registration Number: NCT01118338

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge

Phase 2

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Loteprednol etabonate suspension
Drug: Loteprednol etabonate base (QD)
Drug: Loteprednol etabonate base (BID)
Drug: Loteprednol etabonate base (QID)
Drug: Vehicle of loteprednol etabonate

First Posted Date: 2010-04-21

Last Posted Date: 2012-03-21

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 101

Registration Number: NCT01107405

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Phase 3

Completed

Conditions: Inflammation
Pain

Interventions: Drug: Vehicle of Loteprednol Etabonate
Drug: Loteprednol etabonate

First Posted Date: 2010-02-02

Last Posted Date: 2012-01-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 407

Registration Number: NCT01060072

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant

Completed

Conditions: Inflammation
Uveitis

Interventions: Procedure: Fluocinolone Acetonide 0.59 mg
Procedure: Fluocinolone Acetonide 2.1 mg

First Posted Date: 2010-02-02

Last Posted Date: 2019-06-21

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 98

Registration Number: NCT01060787

Locations: 🇺🇸
Ophthalmic Partners of Boston, Boston, Massachusetts, United States

Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis

Phase 3

Completed

Conditions: Conjunctivitis
Keratitis
Blepharitis

Interventions: Drug: Loteprednol and tobramycin
Drug: Tobramycin and dexamethasone

First Posted Date: 2009-12-09

Last Posted Date: 2012-02-28

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 357

Registration Number: NCT01028027

Locations: 🇸🇬
Bausch & Lomb Inc, Singapore, Singapore

A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution

Not Applicable

Completed

Conditions: Ocular Discomfort

Interventions: Device: Bausch & Lomb Multi-Purpose Solution
Device: Ciba's Multi-Purpose Solution

First Posted Date: 2009-12-03

Last Posted Date: 2011-08-15

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 312

Registration Number: NCT01024751

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Phase 3

Completed

Conditions: Inflammation
Pain

Interventions: Drug: Vehicle of Loteprednol Etabonate
Drug: Loteprednol Etabonate

First Posted Date: 2009-11-10

Last Posted Date: 2012-01-09

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 406

Registration Number: NCT01010633

Locations: 🇺🇸
Bausch & Lomb, Inc., Rochester, New York, United States

Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers

Not Applicable

Completed

Conditions: Vision Disorders

Interventions: Device: SofLens59 contact lens
Device: PureVision Multi-Focal contact lenses

First Posted Date: 2009-09-28

Last Posted Date: 2015-03-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 272

Registration Number: NCT00985231

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

Phase 2

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Vehicle (Placebo)
Drug: Besifloxacin

First Posted Date: 2009-09-09

Last Posted Date: 2012-03-29

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 474

Registration Number: NCT00972777

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Moxifloxacin
Drug: Besifloxacin
Drug: Gatifloxacin

First Posted Date: 2009-05-21

Last Posted Date: 2011-12-09

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 119

Registration Number: NCT00905762

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy